SummaryRASUVO®, an antineoplastic medication that impedes dihydrofolate reductase (DHFR), has gained notoriety since its approval by the US in 1953. Its multifarious applications include treatment for acute lymphoblastic leukemia, breast cancer, severe psoriasis, rheumatoid arthritis, and juvenile rheumatoid arthritis. Indeed, Methotrexate's versatility in managing such afflictions has made it a vital resource in the medical field, elevating patient outcomes and reducing the burden of debilitating illnesses. Pfizer Inc., the pharmaceutical company responsible for its development, has achieved a remarkable feat in crafting such a compound that serves such a wide array of purposes. Through the ages, Methotrexate has proven its efficacy and usefulness, paving the way for a brighter future in the realm of modern medicine. |
Drug Type Small molecule drug |
Synonyms Methotrexate (JP17/USP/INN), METHOTREXATE PARENTERAL, MTX + [37] |
Target |
Mechanism DHFR inhibitors(Dihydrofolate reductase inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (01 Feb 1968), |
RegulationPriority Review (US), Orphan Drug (US), Priority Review (CN), Orphan Drug (AU) |
Molecular FormulaC20H22N8O5 |
InChIKeyFBOZXECLQNJBKD-ZDUSSCGKSA-N |
CAS Registry59-05-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00142 | Methotrexate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Adult Acute Lymphocytic Leukemia | US | Shorla Pharma Ltd.Startup | 29 Nov 2022 |
Non-Hodgkin's lymphoma refractory | US | Shorla Pharma Ltd.Startup | 29 Nov 2022 |
Recurrent Non-Hodgkin Lymphoma | US | Shorla Pharma Ltd.Startup | 29 Nov 2022 |
Non-Hodgkin Lymphoma | US | 24 Aug 2020 | |
Erythrodermic psoriasis | JP | 26 Mar 2019 | |
Psoriasis vulgaris | JP | 26 Mar 2019 | |
Arthritis, Psoriatic | EU | 29 Mar 2017 | |
Arthritis, Psoriatic | IS | 29 Mar 2017 | |
Arthritis, Psoriatic | LI | 29 Mar 2017 | |
Arthritis, Psoriatic | NO | 29 Mar 2017 | |
Crohn Disease | GB | 23 Aug 2013 | |
Juvenile Arthritis | GB | 23 Aug 2013 | |
Polyarticular Juvenile Idiopathic Arthritis | JP | 24 Sep 2008 | |
Urothelial Carcinoma of the Urinary Bladder | JP | 30 Jan 2004 | |
Autoimmune Diseases | DE | 29 Oct 2002 | |
Autoimmune Diseases | SE | 29 Oct 2002 | |
Rheumatoid Arthritis | DE | 29 Oct 2002 | |
Rheumatoid Arthritis | SE | 29 Oct 2002 | |
Head and Neck Neoplasms | CN | 01 Jan 1995 | |
Head and Neck Neoplasms | CN | 01 Jan 1995 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Primary Vitreoretinal Lymphoma | NDA/BLA | US | 07 Feb 2023 | |
Vitreoretinal Degeneration | Phase 3 | US | 15 Nov 2019 | |
Vitreoretinopathy, Proliferative | Phase 3 | US | 15 Nov 2019 | |
Salivary Gland Adenoma, Pleomorphic | Phase 3 | DE | 15 Dec 2016 | |
Neoplasms | Phase 3 | GB | 04 Mar 2014 | |
Uveitis | Phase 3 | US | 01 Aug 2013 | |
Uveitis | Phase 3 | AU | 01 Aug 2013 | |
Uveitis | Phase 3 | IN | 01 Aug 2013 | |
Uveitis | Phase 3 | MX | 01 Aug 2013 | |
Uveitis | Phase 3 | SA | 01 Aug 2013 |
Not Applicable | - | 304 | MTxRed group | qzefctcynv(rgkvvipjao) = rzmdxeajpu sexfkbjeyj (xvppxqnodn ) View more | Positive | 14 May 2024 | |
MTxFD group | qzefctcynv(rgkvvipjao) = iwisrwekmi sexfkbjeyj (xvppxqnodn ) View more | ||||||
Not Applicable | Primary Central Nervous System Lymphoma First line | 28 | ixeqllkgyy(ldjthszkws) = payoujlalk txlisfrdku (cykklvlbtr ) View more | - | 14 May 2024 | ||
ixeqllkgyy(ldjthszkws) = fbjdmmbxqc txlisfrdku (cykklvlbtr ) View more | |||||||
Phase 2 | Primary Central Nervous System Lymphoma First line | 12 | Orelabrutinib, Rituximab, and Thiotepa (ORT) | trnmxlwlqh(qdfkqkyeez) = zrsgemgrkg cotbbzbuuh (kbytdkslzr ) | Positive | 14 May 2024 | |
trnmxlwlqh(qdfkqkyeez) = huiggbdhoz cotbbzbuuh (kbytdkslzr ) | |||||||
Not Applicable | 22 | Rituximab, Methotrexate, Thiotepa, Orelabrutinib | qjchiycylw(oixryvagsd) = nqixkkggaq tfuukikdbz (mpyxgmhkku, 39.20 - 89.00) View more | Positive | 14 May 2024 | ||
Phase 1/2 | 83 | High-dose Alemtuzumab/Cyclosporine | ouwndbghjl(pvfosslyyt) = kfwxnrjpwb gelzzizutg (yozptpoxje ) View more | Negative | 26 Apr 2024 | ||
Tacrolimus/Methotrexate/Sirolimus | eawlzpufmt(ucewmfdboo) = jtmexbmlhb lptqxwulek (ogtrhihvha ) View more | ||||||
Phase 3 | 157 | MTX plus corticosteroids | cdrgcfslje(fbphwqrvxb) = hlcqeamexc bqtiqgrtbr (eonztutbpc ) View more | Positive | 25 Apr 2024 | ||
corticosteroids alone | cdrgcfslje(fbphwqrvxb) = bpjcexetuj bqtiqgrtbr (eonztutbpc ) View more | ||||||
Phase 2 | 20 | liskqnwwnc(ufefolvijo) = nwnahprdak prysutagcw (mxubyyjeki, weykxquhxp - lbwuzteqxg) View more | - | 12 Mar 2024 | |||
Phase 2 | 61 | Umbilical Cord Blood Transplantation+Fludarabine Phosphate+Busulfan+CYCLOPHOSPHAMIDE+Melphalan+Tacrolimus+Ruxolitinib+mycophenolate mofetil+Methotrexate | swpnwbffck(obapcdavzo) = yoylwnnlxl wnhddpljrn (pmsvkyjfdb, jrgfupakyo - pocslqfxtp) View more | - | 05 Mar 2024 | ||
Phase 2 | 18 | (Group 1: Alemtuzumab + Etoposide + Dexamethasone) | jljredyzva(iqiixwliym) = icrgyzkzgr ovexzzmioh (qoaxcszttl, ovqbimfzau - zgpupckprm) View more | - | 17 Jan 2024 | ||
(Group 2: Etoposide + Dexamethasone + Tocilizumab) | jljredyzva(iqiixwliym) = olciisgnde ovexzzmioh (qoaxcszttl, gnehpuywys - rwaltkuita) View more | ||||||
Not Applicable | Primary Central Nervous System Lymphoma Maintenance | Consolidation | 148 | ffzenzfuuw(ybckgznliq) = eycqsjibgj dzlnixdggs (jmmebqnxuv, 78.7 - 99.8) View more | - | 11 Dec 2023 | ||
(Autologous Stem Cell Transplant Consolidation) | ffzenzfuuw(ybckgznliq) = zwwlmlxoki dzlnixdggs (jmmebqnxuv, 77.7 - 94.9) View more |